Daxxify and Jeuveau are both botulinum toxin type A, and both are approved in the US for frown lines between the eyebrows.
They were built around opposite selling points. Daxxify was launched on lasting longer. Jeuveau was launched on costing less. Neither claim tells you much about how the result will look.
The evidence behind them is not equal, though, and it is not equal in a way most comparisons miss. Jeuveau was tested directly against Botox in a large trial built for that purpose. Daxxify's main trials were against a placebo only. That does not make Jeuveau better — but it does mean one of these products has been through a large head-to-head against an established competitor and the other has not.
Approved in the US in 2022, by Revance.
Approved in the US in 2019, by Evolus.
Jeuveau is a cosmetic-only product in the US. It has no FDA approval for any medical condition.
The only one of the main brands with no human blood protein in it.
A protein complex of about 900 kDa around the toxin.
The two main trials compared Daxxify against an inactive injection. An earlier, smaller study did compare it with Botox, but it was designed to choose a dose rather than to settle which works better.
A large trial compared Jeuveau directly against Botox at the standard dose.
Half the people treated still had none-or-mild frown lines at that point.
Jeuveau's label states no duration, and its trials measured the result at fixed dates rather than following people until it wore off.
The price was cut within about a year.
Jeuveau's main trial gave one group Jeuveau, one group Botox, and one group a placebo. Both real products beat the placebo by a wide margin, and Jeuveau performed comparably to Botox.
One important caveat: that trial was designed to show Jeuveau was not worse than Botox, not to show it was better. Jeuveau's number came out slightly higher than Botox's. That gap is not a win — the trial was not built to detect one, and reporting it as "Jeuveau beat Botox" misreads the study.
Daxxify's main trials compared it against an inactive injection. That is enough to earn FDA approval, and it tells you Daxxify works. It does not tell you how Daxxify stacks up against anything else on the market. There was an earlier study that included Botox as a comparison, but it was a smaller, dose-finding study — built to pick a dose, not to measure which product performs better or lasts longer.
Daxxify's six-month reputation comes from its own trials, where half the people treated still had frown lines rated none or mild at about 24 weeks.
That is a genuine finding. What it is not is a comparison — no trial has put Daxxify against Jeuveau, and the two products' numbers came from studies that judged results at different moments. Anyone quoting "six months versus three" is combining figures that were never meant to sit in the same sentence.
The market gave its own verdict, for what it is worth: the premium price did not hold, and it was reduced within roughly a year of launch.
Go to an emergency department or call 911. Do not wait for a call back. These are rare, but they are the symptoms named in the FDA boxed warning that every botulinum toxin product carries, deaths have been reported, and they can begin hours or even weeks after treatment.
If a vision change is sudden or severe, seek urgent care rather than waiting.